{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:55:29Z","timestamp":1793850929358,"version":"4.6.1"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010567","name":"Secretar\u00eda de Estado de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide. The increase in the prevalence of MASLD is linked to the global rise in obesity. MASLD encompasses a disease spectrum beginning with simple steatosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocarcinoma. Clinical studies highlight the bidirectional relationship between MASLD and systemic arterial hypertension (SAH), showing that MASLD patients have a higher risk of developing SAH. Likewise, hypertensive patients show an increased susceptibility to MASLD, suggesting mutual pathogenic mechanisms. Inflammation is a shared pathway between these two entities; MASLD pathogenesis encompasses hepatic lipotoxicity, inducing the release of pro-inflammatory mediators, which promote systemic inflammation, contributing to vascular remodeling, increased blood pressure, and deregulating the renin-angiotensin system (RAS), potentially contributing to SAH. On the other hand, chronic hypertension promotes hepatic inflammation through immune and neuroendocrine pathways, favoring progression from MASLD to MASH. This review, emphasizing the pro-inflammatory factors, explores the inflammatory crosstalk between MASLD and SAH. Understanding this interplay provides a comprehensive perspective on chronic inflammation that could link liver and vascular pathologies, offering potential therapeutic targets for treating both conditions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1620585","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:12:40Z","timestamp":1757045560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension"],"prefix":"10.3389","volume":"16","author":[{"given":"Helena","family":"Solleiro-Villavicencio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Viurcos-Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alfredo","family":"Aguayo-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Fernando","family":"Pineda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda Ang\u00e9lica","family":"M\u00e9ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B2","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep ."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149641","article-title":"The \u201cDomino effect\u201d in MASLD: The inflammatory cascade of steatohepatitis","volume":"54","author":"Mladeni\u0107","year":"2024","journal-title":"Eur J Immunol ."},{"key":"B4","doi-asserted-by":"crossref","unstructured":"Seravalle\n              G\n            \n            \n              Grassi\n              G\n            \n          \n          Essential hypertension. Primer on the autonomic nervous system\n          \n          2023","DOI":"10.1016\/B978-0-323-85492-4.00096-X"},{"key":"B5","author":"Golubeva","year":""},{"key":"B6","article-title":"Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension","volume":"46","author":"Nakagami","year":"2022","journal-title":"Hypertension Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/life14091080","article-title":"Exploring the th2 response in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): A potential modulator of the renin-angiotensin system (RAS) pathway in hypertension development","volume":"14","author":"M\u00e9ndez-Garc\u00eda","year":"2024","journal-title":"Life"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-30997-y","article-title":"Decreased Paneth cell \u03b1-defensins promote fibrosis in a choline-deficient L-amino acid-defined high-fat diet-induced mouse model of nonalcoholic steatohepatitis via disrupting intestinal microbiota","volume":"13","author":"Nakamura","year":"2023","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.3390\/ijms25084397","article-title":"The relationship between pathogenesis and possible treatments for the MASLD-cirrhosis spectrum","volume":"25","author":"Vidal-Cevallos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-017-0572-9","article-title":"A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease","volume":"16","author":"Chen","year":"2017","journal-title":"Lipids Health Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.05.008","article-title":"Innate-like T cells in liver disease","volume":"45","author":"Yang","year":"2024","journal-title":"Trends Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1437046","article-title":"Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Abdelnabi","year":"2024","journal-title":"Front Immunol ."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107615","article-title":"Platelets fuel the inflammasome activation of innate immune cells","volume":"31","author":"Rolfes","year":"2020","journal-title":"Cell Rep ."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050641","article-title":"Chronic inflammation\u2014A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue","volume":"58","author":"Petrescu","year":"2022","journal-title":"Medicina (B Aires)"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease \u2013 novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.21037\/dmr-21-87","article-title":"Role of the chemokine system in liver fibrosis: a narrative review","volume":"5","author":"Poulsen","year":"2022","journal-title":"Dig Med Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318082","article-title":"Pathophysiology of hypertension: the mosaic theory and beyond","volume":"128","author":"Harrison","year":"2021","journal-title":"Circ Res ."},{"key":"B21","unstructured":"Hypertension"},{"key":"B22","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00618.2015","article-title":"Biochemical evaluation of the renin-angiotensin system: The good, bad, and absolute","volume":"310","author":"Chappell","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol ."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.977039","article-title":"Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations","volume":"16","author":"M\u00e9ndez-Garc\u00eda","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"B25","first-page":"1","volume-title":"The renin-angiotensin system : A key role in","author":"El-Arif","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01356-w","article-title":"Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications","volume":"20","author":"Valensi","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpab124","article-title":"The sympathetic nervous system in hypertension: roadmap update of a long journey","volume":"34","author":"Grassi","year":"2021","journal-title":"Am J Hypertens ."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1113\/JP272944","article-title":"Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis","volume":"595","author":"Adlan","year":"2017","journal-title":"J Physiol ."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1098725","article-title":"Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"107050","DOI":"10.1016\/j.phrs.2023.107050","article-title":"Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis","volume":"200","author":"Caiazzo","year":"2024","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-021-01128-7","article-title":"Interleukin 17A: key player in the pathogenesis of hypertension and a potential therapeutic target","volume":"23","author":"Davis","year":"2021","journal-title":"Curr Hypertens Rep ."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.199265","article-title":"Interferon-\u03b3 signaling inhibition ameliorates angiotensin ii-induced cardiac damage","volume":"60","author":"Mark\u00f3","year":"2012","journal-title":"Hypertension ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-022-01497-3","article-title":"Association between hypertension and neurovascular inflammation in both normal-appearing white matter and white matter hyperintensities","volume":"11","author":"Sol\u00e9-Guardia","year":"2023","journal-title":"Acta Neuropathol Commun ."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpac081","article-title":"More evidence links microglia and neuroinflammation with hypertension","volume":"35","author":"Lima","year":"2022","journal-title":"Am J Hypertens"},{"key":"B35","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.4103\/1673-5374.336869","article-title":"Neuroinflammation as a mechanism linking hypertension with the increased risk of Alzheimer\u2019s disease","volume":"17","author":"Bajwa","year":"2022","journal-title":"Neural Regener Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319816","article-title":"Gut microbiome and neuroinflammation in hypertension","volume":"130","author":"Richards","year":"2022","journal-title":"Circ Res ."},{"key":"B37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41440-024-01759-8","article-title":"The causal relationship between non-alcoholic fatty liver disease, hypertension, and cardiovascular diseases: implications for future research","volume":"47","author":"Maeda","year":"2024","journal-title":"Hypertension Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.21712","article-title":"Immunomodulatory activity of cytokines in hypertension: A vascular perspective","volume":"81","author":"dos Passos","year":"2024","journal-title":"Hypertension ."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/CD9.0000000000000113","article-title":"Overview of the association between non-alcoholic fatty liver disease and hypertension","volume":"4","author":"Kakouri","year":"2024","journal-title":"Cardiol Discov ."},{"key":"B41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cimb47050357","article-title":"The mechanisms of chronic inflammation in obesity and potential therapeutic strategies: A narrative review","volume":"47","author":"Gkrinia","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol ."},{"key":"B43","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B44","first-page":"17","article-title":"IL-1\u03b2 and IL-10: diagnostic and prognostic potential of cytokines in the assessment of progression of non-alcoholic fatty liver disease in patients with hypertension","author":"Zhelezniakova","year":"2021","journal-title":"EUREKA: Health Sci ."},{"key":"B45","article-title":"Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling","volume":"281","author":"Soo","year":"2006","journal-title":"J Biol Chem"},{"key":"B46","article-title":"ChIP-atlas","author":"Oki","year":"2015","journal-title":"Target genes"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2012.10.553","article-title":"IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes\/macrophages","volume":"54","author":"Bhattacharjee","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"B48","doi-asserted-by":"crossref","first-page":"9963","DOI":"10.3390\/ijms24129963","article-title":"Close relationship between systemic arterial and portal venous pressure in an animal model with healthy liver","volume":"24","author":"Lazaro","year":"2023","journal-title":"Int J Mol Sci ."},{"key":"B49","unstructured":"CXCL9 C-X-C motif chemokine ligand 9 [Homo sapiens (human)] - Gene - NCBI"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-120","article-title":"(fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis","volume":"13","author":"Semba","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cmet.2021.04.018","article-title":"PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease","volume":"33","author":"Moreno-Fernandez","year":"2021","journal-title":"Cell Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.09.032","article-title":"CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt","volume":"62","author":"Berres","year":"2015","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"crossref","first-page":"862278","DOI":"10.3389\/fmed.2022.862278","article-title":"SPP1 and CXCL9 promote non-alcoholic steatohepatitis progression based on bioinformatics analysis and experimental studies","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.09.032","article-title":"CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt","volume":"62","author":"Berres","year":"2015","journal-title":"J Hepatol ."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2016.16","article-title":"C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication","volume":"18","author":"Xu","year":"2016","journal-title":"Expert Rev Mol Med"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.03.053","volume-title":"Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans","author":"Wasmuth","year":"2009"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25545","article-title":"Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice","volume":"55","author":"Sahin","year":"2012","journal-title":"Hepatology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.3390\/cancers13205090","article-title":"The chemokine-based peptide, CXCL9(74-103), inhibits angiogenesis by blocking heparan sulfate proteoglycan-mediated signaling of multiple endothelial growth factors","volume":"13","author":"De Zutter","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B59","doi-asserted-by":"publisher","first-page":"107799","DOI":"10.1016\/j.pharmthera.2020.107799","article-title":"Role of inflammatory chemokines in hypertension","volume":"223","author":"Mikolajczyk","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90444.2008","article-title":"Hypertension in mice lacking the CXCR3 chemokine receptor","volume":"296","author":"Hsu","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16861","article-title":"Regulation of pulmonary fibrosis by chemokine receptor CXCR3","volume":"114","author":"Jiang","year":"2004","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.00689","article-title":"Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension","volume":"62","author":"Youn","year":"2013","journal-title":"Hypertension ."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.00689","article-title":"The \u201cDomino effect\u201d in MASLD: The inflammatory cascade of steatohepatitis","volume":"54","author":"Mladeni\u0107","year":"2024","journal-title":"Eur J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0303093","article-title":"Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation","volume":"74","author":"Harvey","year":"2003","journal-title":"J Leukoc Biol"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2018.05.128","article-title":"CXCL10-induced IL-9 promotes liver fibrosis via Raf\/MEK\/ERK signaling pathway","volume":"105","author":"Guo","year":"2018","journal-title":"Biomedicine Pharmacotherapy ."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in non-alcoholic fatty liver disease: A systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol ."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19068","article-title":"C-X-C motif chemokine 10 impairs autophagy and autolysosome formation in non-alcoholic steatohepatitis","volume":"7","author":"Zhang","year":"2017","journal-title":"Theranostics."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.7150\/thno.44960","article-title":"Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2008.15","article-title":"High serum levels of CXC chemokine ligand 10 in untreated essential hypertension","volume":"22","author":"Antonelli","year":"2008","journal-title":"J Hum Hypertens"},{"key":"B70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2020.107799","article-title":"Role of inflammatory chemokines in hypertension","author":"Mikolajczyk","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2020.107799","article-title":"Role of inflammatory chemokines in hypertension","volume":"70","author":"Mikolajczyk","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e12700","DOI":"10.1371\/journal.pone.0012700","article-title":"CXCL10 can inhibit endothelial cell proliferation independently of CXCR3","volume":"5","author":"Campanella","year":"2010","journal-title":"PloS One"},{"key":"B73","unstructured":"Vascular cell adhesion molecule-1 - meSH - NCBI"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J Clin Invest."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.102","article-title":"Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease","volume":"41","author":"Lefere","year":"2017","journal-title":"Int J Obes (Lond)."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2021.209991","article-title":"Role of circulating vascular cell adhesion protein\u20131 as a biomarker in non-alcoholic fatty liver disease","volume":"86","author":"Samir","year":"2022","journal-title":"Egyptian J Hosp Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983255","article-title":"Liver sinusoidal endothelial cell expressed vascular cell adhesion molecule 1 promotes liver fibrosis","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B78","first-page":"01.31.634947","article-title":"Hepatic arterial flow-induced portal tract fibrosis in portal hypertension: the role of VCAM-1 and osteopontin-expressing macrophages","volume":"2025","author":"Ma","year":"2025","journal-title":"bioRxiv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825459","article-title":"Blocking VCAM-1 prevents angiotensin II-induced hypertension and vascular remodeling in mice","author":"Yin","year":"2022","journal-title":"Front Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"166170","DOI":"10.1016\/j.bbadis.2021.166170","article-title":"VCAM-1 as a predictor biomarker in cardiovascular disease","volume":"1867","author":"Troncoso","year":"2021","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Disease."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(01)00125-X","article-title":"Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1","volume":"12","author":"Parissis","year":"2001","journal-title":"Eur J Intern Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.09.005","article-title":"Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension","volume":"19","author":"Cottone","year":"2006","journal-title":"Am J Hypertens"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/404025","article-title":"Involvement of inflammation and adverse vascular remodelling in the blood pressure raising effect of repeatedly heated palm oil in rats","volume":"2012","author":"Ng","year":"2012","journal-title":"Int J Vasc Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1081\/CEH-120025335","article-title":"Patients with Essential Hypertension Present Higher Levels of sE-Selectin and sVCAM-1 Than Normotensive Volunteers","volume":"25","author":"Palomo","year":"2003","journal-title":"Clin Exp Hypertens"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 Inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2264-z","article-title":"The concentration of tumor necrosis factor-\u03b1 determines its protective or damaging effect on liver injury by regulating Yap activity","volume":"11","author":"Zhao","year":"2020","journal-title":"Cell Death Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatol ."},{"key":"B88","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.redox.2023.102870","article-title":"TNF\u03b1 is a key trigger of inflammation in diet-induced non-obese MASLD in mice","author":"Burger","year":"2023","journal-title":"Redox Biol ."},{"key":"B89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10238-015-0347-4","article-title":"Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients","volume":"16","author":"Paredes-Turrubiarte","year":"2016","journal-title":"Clin Exp Med ."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.109.144154","article-title":"Tumor necrosis factor-alpha: a possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension","volume":"55","author":"Mazor","year":"2010","journal-title":"Hypertension ."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19464","article-title":"Responses to ang II (Angiotensin II), salt intake, and lipopolysaccharide reveal the diverse actions of TNF-\u03b1 (Tumor necrosis factor-\u03b1) on blood pressure and renal function","volume":"79","author":"Crorkin","year":"2022","journal-title":"Hypertension."},{"key":"B92","first-page":"1","article-title":"Renal tumor necrosis factor \u03b1 Contributes to hypertension in dahl salt-sensitive rats","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"B93","doi-asserted-by":"crossref","DOI":"10.36660\/abc.202190703","article-title":"Efeitos da Terapia com Anti-TNF alfa na Press\u00e3o Arterial em Pacientes com Hipertens\u00e3o Resistente: Um Estudo Piloto Randomizado, Duplo-Cego e Controlado por Placebo","volume":"116","author":"de Faria","year":"2021","journal-title":"Arq Bras Cardiol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102785","article-title":"The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities","volume":"20","author":"Galozzi","year":"2021","journal-title":"Autoimmun Rev ."},{"key":"B95","first-page":"6495793","article-title":"The role of IL-1 family members and kupffer cells in liver regeneration","volume":"2016","author":"Tan","year":"","journal-title":"BioMed Res Int"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M412220200","article-title":"Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice","volume":"280","author":"Isoda","year":"2005","journal-title":"J Biol Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02014","article-title":"Interleukin-1 family cytokines: keystones in liver inflammatory diseases","volume":"10","author":"Barbier","year":"2019","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107265","article-title":"IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis","volume":"9","author":"Negrin","year":"2014","journal-title":"PloS One ."},{"key":"B99","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatol ."},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1038\/ni.2022","article-title":"Fatty acid\u2013induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat Immunol"},{"key":"B101","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1\u03b2 Inhibition on blood pressure, incident hypertension, and residual inflammatory risk: A secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2019","journal-title":"Hypertension ."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168639","article-title":"Interleukin-1\u03b2 in multifactorial hypertension: inflammation, vascular smooth muscle cell and extracellular matrix remodeling, and non-coding RNA regulation","volume":"22","author":"Melton","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 family and its role in atherosclerosis","volume":"24","author":"Rivera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: From physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J Hepatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007929","article-title":"IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis","volume":"4","author":"Mas","year":"2009","journal-title":"PloS One ."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.059","article-title":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis","volume":"103","author":"Dogru","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B108","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12291-011-0121-7","article-title":"Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease","volume":"26","author":"Das","year":"2011","journal-title":"Indian J Clin Biochem"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-023-05759-5","article-title":"The role of the soluble interleukin-6 receptor in the progression of nonalcoholic fatty liver disease","volume":"174","author":"Kurbatova","year":"2023","journal-title":"Bull Exp Biol Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0171","article-title":"IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity, and associated with liver stiffness and fibrosis in fatty liver disease","volume":"72","author":"Gunes","year":"2023","journal-title":"Diabetes ."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.75","article-title":"Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice","volume":"90","author":"Yamaguchi","year":"2010","journal-title":"Lab Invest"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.30.541","article-title":"Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients","volume":"30","author":"Naya","year":"","journal-title":"Hypertens Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.91","article-title":"The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"25","author":"Lakoski","year":"2011","journal-title":"J Hum Hypertens"},{"key":"B114","unstructured":". Local Renin-Angiotensin System at Liver and Crosstalk with Hepatic Diseases\n          \n          \n            \n              Taskin\n              E\n            \n            \n              Guven\n              C\n            \n            \n              Taskin\n              E\n            \n            \n              Guven\n              C\n            \n          \n          Renin-angiotensin system - past, present and future\n          \n          2017"},{"key":"B115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab ."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq078","article-title":"Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice","volume":"87","author":"Kobara","year":"2010","journal-title":"Cardiovasc Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.158071","article-title":"Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2\/signal transducer and activator of transcription 3 activation","volume":"56","author":"Brands","year":"2010","journal-title":"Hypertension"},{"key":"B118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/life13020419","article-title":"The essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease","volume":"13","author":"Olveira","year":"2023","journal-title":"Life (Basel)"},{"key":"B120","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol ."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.01.027","article-title":"Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid \u03b2-oxidation","volume":"1863","author":"Shen","year":"2017","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Disease."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-017-0215-y","article-title":"The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice","volume":"18","author":"He","year":"2017","journal-title":"BMC Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.09.024","article-title":"3, 3\u2019-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg\/Th17 cells to Treg dominance","volume":"23","author":"Liu","year":"2014","journal-title":"Int Immunopharmacol ."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"B125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefro.2020.11.009","article-title":"Interleuquina-17A: posible mediador y diana terap\u00e9utica en la hipertensi\u00f3n","volume":"41","author":"Rodrigues-Diez","year":"2021","journal-title":"Nefrolog\u00eda ."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011450","article-title":"Elevated eosinophils as a feature of inflammation associated with hypertension in virally suppressed people living with HIV","volume":"9","author":"Masenga","year":"2020","journal-title":"J Am Heart Assoc ."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07237","article-title":"Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans","volume":"68","author":"Itani","year":"2016","journal-title":"Hypertension ."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02604","article-title":"\u03b3\u03b4T Cell-derived interleukin-17A via an interleukin-1\u03b2-dependent mechanism mediates cardiac injury and fibrosis in hypertension","volume":"64","author":"Li","year":"2014","journal-title":"Hypertension"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07493","article-title":"nterleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension","volume":"68","author":"Norlander","year":"2016","journal-title":"Hypertension ."},{"key":"B130","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/cvr\/cvs422","article-title":"Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension","volume":"97","author":"Nguyen","year":"2013","journal-title":"Cardiovasc Res"},{"key":"B131","article-title":"Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling","volume":"281","author":"Soo","year":"","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.011585","article-title":"Early growth response protein-1 (Egr-1) is preferentially expressed in T helper type 2 (Th2) cells and is involved in acute transcription of the Th2 cytokine interleukin-4","volume":"285","author":"Lohoff","year":"2010","journal-title":"J Biol Chem"},{"key":"B133","article-title":"Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells","volume":"43","author":"Liang","year":"","journal-title":"Acta Pharmacol Sin"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13610","article-title":"Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality","volume":"38","author":"Lehmann","year":"2018","journal-title":"Liver Int ."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:12:51Z","timestamp":1757045571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":134,"alternative-id":["10.3389\/fimmu.2025.1620585"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620585","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1620585"}}